New diabetes medication that avoids nausea and vomiting
Second generation GLP-1 agonists without nausea/emesis side effects
This study is testing a new type of blood sugar-lowering medication that aims to help people with diabetes without causing the usual side effects like nausea, using a special formula that makes it easier on the body.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pennsylvania NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-10791818 on NIH RePORTER |
What this research studies
This research focuses on developing a new type of medication based on glucagon-like peptide-1 (GLP-1) that helps lower blood sugar levels without causing common side effects like nausea and vomiting. The approach involves creating a modified version of an existing GLP-1 drug that minimizes its effects on the brain, which are responsible for these unpleasant side effects. By using a vitamin B12 conjugate, the researchers aim to ensure that the medication effectively regulates blood sugar while being well-tolerated by patients. The study will involve preclinical testing in animal models to evaluate the safety and efficacy of this new drug formulation.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with type 2 diabetes who experience side effects from current GLP-1 medications.
Not a fit: Patients who do not have type 2 diabetes or those who are not affected by the side effects of existing GLP-1 medications may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a more effective and tolerable treatment option for patients with type 2 diabetes.
How similar studies have performed: Previous research has shown promise in developing modified GLP-1 therapies, but this specific approach is novel and has not been extensively tested.
Where this research is happening
Philadelphia, United States
- University of Pennsylvania — Philadelphia, United States (Active)
Researchers
- Principal investigator: Hayes, Matthew R — University of Pennsylvania
- Study coordinator: Hayes, Matthew R
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.